December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

265.15 USD UNCHANGED
Streaming Delayed Price Updated: 5:34 AM EST, Jan 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
57 58 Next >
Recent Analysis Shows Aflac, Biogen, Oasis Petroleum, Twilio, Neothetics, and McDonald's Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aflac Incorporated... 
From GlobeNewswire News Releases
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral,... 
From Business Wire News Releases
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral,... 
From Business Wire News Releases
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of December 11, 2017. 
From Business Wire News Releases
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference 
From Business Wire News Releases
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
From ACN Newswire
Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation. 
From Business Wire News Releases
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
BIOGEN PRESENTS NEW DATA FROM LONG-TERM EXTENSION OF PHASE 1B STUDY OF INVESTIGATIONAL ALZHEIMER’S DISEASE TREATMENT ADUCANUMAB 
From Business Wire News Releases
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy 
From Business Wire News Releases
Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference
Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference 
From Business Wire News Releases
Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Biogen and Ionis have been awarded the prestigious 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA® (nusinersen). 
From Business Wire News Releases
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis 
From Business Wire News Releases
Biogen Reports Quarterly Revenues of $3.1 Billion
Biogen Reports Quarterly Revenues of $3.1 Billion 
From Business Wire News Releases
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG
BIOGEN INCREASES PROFIT POTENTIAL ON INVESTIGATIONAL ALZHEIMER’S DISEASE TREATMENT ADUCANUMAB THROUGH AMENDED AGREEMENT WITH NEURIMMUNE HOLDING AG 
From Business Wire News Releases
Research Report Identifies Sherwin-Williams, Charter Communications, Biogen, C. R. Bard, Mohawk Industries, and Humana Inc. with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Sherwin-Williams... 
From GlobeNewswire News Releases
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today... 
From Business Wire News Releases
Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle MS at the seventh joint meeting of ECTRIMS/ACTRIMS. 
From Business Wire News Releases
Align Biopharma Introduces New Technology Standard to Enable Single Sign-on for Healthcare Providers
Align Biopharma finalized an identity management technology standard that will make it easier for HCPs to access online content across life sciences. 
From Business Wire News Releases
Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Biogen’s SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with SMA. 
From Business Wire News Releases
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017. 
From Business Wire News Releases
Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
Biogen (NASDAQ: BIIB) announced the appointment of Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective today. 
From Business Wire News Releases
Alzheimer's Disease: Cannabis Formulation Shows Promise
NetworkNewsWire Editorial Coverage 
From PR Newswire
Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
Biogen (NASDAQ: BIIB) announced today the appointment of Dr. Sanjay Jariwala as Senior Vice President, Worldwide Medical. 
From Business Wire News Releases
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference. 
From Business Wire News Releases
Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment... 
From Business Wire News Releases
Technical Snapshots for these Biotech Stocks -- Gilead Sciences, Biogen, bluebird bio, and BioMarin Pharma
From PR Newswire
IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
IMRALDI®, BIOGEN’S ADALIMUMAB BIOSIMILAR REFERENCING HUMIRA®, IS APPROVED IN THE EUROPEAN UNION 
From Business Wire News Releases
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,... 
From GlobeNewswire News Releases
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,... 
From GlobeNewswire News Releases
Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Biogen (NASDAQ:BIIB) today announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences (BTMS). Dr. Villalobos will lead Biogen’s BTMS... 
From Business Wire News Releases
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
57 58 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.